



## Review

# The bare necessities? A realist review of necessity argumentations used in health care coverage decisions



Tineke Kleinhout-Vliek\*, Antoinette de Bont, Bert Boer

Institute of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands

## ARTICLE INFO

### Article history:

Received 9 November 2016

Received in revised form 26 April 2017

Accepted 27 April 2017

### Keywords:

Necessary health care  
Health care coverage  
Decision-making

## ABSTRACT

**Context:** Policy makers and insurance companies decide on coverage of care by both calculating (cost-) effectiveness and assessing the necessity of coverage.

**Aim:** To investigate argumentations pertaining to necessity used in coverage decisions made by policy makers and insurance companies, as well as those argumentations used by patients, authors, the public and the media.

**Methods:** This study is designed as a realist review, adhering to the RAMESES quality standards. Embase, Medline and Web of Science were searched and 98 articles were included that detailed necessity-based argumentations.

**Results:** We identified twenty necessity-based argumentation types. Seven are only used to argue in favour of coverage, five solely for arguing against coverage, and eight are used to argue both ways. A positive decision appears to be facilitated when patients or the public set the decision on the agenda. Moreover, half the argumentation types are only used by patients, authors, the public and the media, whereas the other half is also used by policy makers and insurance companies. The latter group is more accepted and used in more different countries.

**Conclusion:** The majority of necessity-based argumentation types is used for either favouring or opposing coverage, and not for both. Patients, authors, the public and the media use a broader repertoire of argumentation types than policy makers and insurance companies.

© 2017 Elsevier B.V. All rights reserved.

## 1. Introduction

Public outrage often ensues when decision makers exclude forms of care, such as orphan drugs or expensive cancer medicines, based on an incremental cost-effectiveness ratio (ICER) that is below par. This outrage not infrequently precedes a reversal of the decision [1,2]. At the same time, however, not all forms of care with a sufficiently low ICER are covered. Viagra, for example, is highly effective and not that expensive, but almost never provided by the state; decision makers deem it unnecessary to do so [3,4]. Hence, (cost-) effectiveness is not the decisive factor in all funding decisions. In these situations, another factor trumps it: the perceived *necessity* of coverage. To aid operationalisation, this paper will survey the content, use and context of the necessity criterion, an umbrella term for need- and solidarity-related argumentations used – not just decisively, and not just in coverage decisions made by policy makers and insurance companies.

In this paper, we will review argumentations underpinning the necessity, or lack thereof, of coverage of a certain treatment or therapy, as explicated in academic literature. To cast our net wide, we have chosen to include not only ‘actual’ decisions, that is, coverage decisions made by policy makers and insurance companies, but also what we term ‘hypothetical’ coverage decisions. The latter type generally comes in the form of surveys (of, e.g., decision makers or the public) or ethical or economic analyses exploring possible reasons for (denial of) coverage. By examining both actual and hypothetical decisions we hope to provide insight into all potential considerations that may be invoked when deciding whether the coverage of a therapy or treatment is thought to be necessary. This is relevant as surveys and public opinion are considered of note (and of use) within coverage decision making practice [5,6], as are scholarly reflections, as exemplified by the international take-up of the accountability for reasonableness framework [7,8].

### 1.1. Objectives and focus of review

We followed the realist review method as described in the RAMESES publication standard [9]. This method is used to review

\* Corresponding author.

E-mail address: [vliek@bmg.eur.nl](mailto:vliek@bmg.eur.nl) (T. Kleinhout-Vliek).

sundry literatures on a specific policy intervention, in order to describe why and how these interventions do what they do in their context. Using this method, researchers aim to uncover what works, for whom, and in what circumstances by conceptualising meta-level theories that detail patterns of how mechanisms-in-contexts lead to certain outcomes [10–12]. In such an iterative research process, we refined how argumentations bearing upon necessity of coverage (mechanism) are used in justifying both actual and hypothetical coverage decisions (outcome), as found in academic literature. These decisions are made in context: by different decision makers from different countries, and, in case of actual decisions, placed on the decision agenda by different actors. Thus, the argumentations may be seen as interventions that have a proposed or actual outworking, also depending on contexts they are situated in. This review will address the following questions:

1. Which, if any, argumentations (mechanisms) are currently used in hypothetical and actual coverage decisions to justify whether coverage of a treatment is, or is not, necessary?
2. How do these argumentations justify the hypothetical and actual coverage decisions (outcomes) for different treatments, in different countries, put on the agenda by different agents (contexts)?

## 2. Methods

### 2.1. Rationale for using realist synthesis

Little attention has been given to “the problem of operationalizing for decision makers essentially qualitative and normative criteria such as whether the technology serves an ‘ethical’ or ‘medically necessary’ purpose” [13]. Furthermore, “social and ethical parameters of value (...) are anticipated to become as critical for reimbursement decisions (...) as economic and clinical criteria” [14]. In light of the lack of operationalisation and its (potentially) crucial role in coverage decisions, we conducted a literature review of the argumentation types that fall under the necessity criterion.

A realist review describes an intervention from different types of literatures, in our case actual coverage decisions (qualitative analyses of coverage decisions or policies) as well as hypothetical ones (economic analyses, ethical analyses, surveys, interviews, and opinion pieces). It searches these articles not just for information on the intervention (that is, the argumentation) but also for how the context (country, agenda setter) may have influenced the use of the intervention and its outcome (the decision including decision type: hypothetical or actual decision). This is subsequently summarised in context-mechanism-outcome patterns. From these patterns, meta-level theories are formulated that explain the working of these interventions-in-context. The primary reason for choosing the realist review method is practical; this method provided a focused lens to zoom in on particular aspects of actual and hypothetical coverage decisions, which in turn aided comparison of a broad variety of articles. Using this method for a non-classical intervention proved, moreover, an interesting methodological issue to grapple with. The second reason for utilising this method lies in its philosophical underpinnings. A realist philosophy holds that actors can and do effectuate change in context, but are themselves shaped by the contexts they are part of. In this sense, it is likely to be acceptable to (social) scientists and policy makers alike.

### 2.2. Scoping the literature and searching processes

As an exploratory foray into grey literature and policy documents yielded too few explicated argumentations, we focused on peer-reviewed literature. For our primary background search thereof [12], we used the conceptualisation of the necessity cri-

**Table 1**

Search terms used in Embase.

```
(‘insurance’/de OR ‘health insurance’/de OR ‘child health insurance’/de OR
‘national health insurance’/de OR ‘private health insurance’/de OR ‘public
health insurance’/de OR ‘national health service’/de OR ‘reimbursement’/de OR
(insurance* OR reimburse* OR (national NEAR/3 (service OR coverage)) OR
(cover* NEAR/6 deci*) OR ((partial* OR polic* OR universal OR unlimited OR
limited OR temporar* OR permanent* OR recommend* OR plan OR plans)
NEAR/3 coverage) OR (basic NEAR/3 package*) OR (health NEAR/3
catalogue*)):ab,ti)
AND
(‘decision making’/de OR ‘ethical decision making’/de OR ‘medical decision
making’/de OR (decision* OR decide OR rationing OR priorit* OR (analys*
NEAR/3 (inclusion OR exclusion)) OR (coverage NEAR/3 (negativ* OR positiv*
OR determin* OR deny OR denial*)):ab,ti) AND (‘resource allocation’/de OR
(coverage OR inclusion* OR funding OR (resource* NEAR/3 allocat*) OR ‘should
be provided’ OR ‘what to provide’):ab,ti)
AND
(‘health care cost’/de OR ‘cost of illness’/de OR ‘economic evaluation’/exp OR
ethics/de OR bioethics/de OR ‘medical ethics’/de OR ‘ethical decision
making’/de OR ‘health care policy’/de OR ‘needs assessment’/de OR (necess*
OR cost* OR (disease* NEAR/3 burden*) OR expenditure* OR solidarit* OR
(therapeutic NEAR/3 (value* OR need*)) OR (budget* NEAR/3 impact*) OR
ethic* OR ‘health benefit’* OR (benefit NEAR/3 (risk OR analysis)) OR ‘health
technology assessment’* OR ‘health care poli’* OR (need* NEAR/3 (assess* OR
healthcare OR health-care)):ab,ti)
NOT
([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
AND
[english]/lim
```

terion in the Netherlands [15], as a request for operationalisation of this criterion from the Dutch Health Care Institute catalysed this study. We subsequently discovered similar and/or underlying conceptualisations and related terminology in other countries, like ‘need’ and ‘solidarity’, which helped inform our search strategy. The full search was conducted in Embase (see Table 1 for search terms), and translated to Medline and Web of Science [16], which is recognised to be an effective combination for reviews [17]. We used three general elements separated by the Boolean operator ‘AND’ as this kept the total number of articles workable (under 6000). These general elements are a) the type of provision, b) the process of decision making, and c) the content in terms of criteria. Utilising a), we aimed for a representative sample, therefore a wide variety of provision types was included (benefit package, health insurance, and/or health catalogue or service). For elements b) and c) specificity was the goal; we zoomed in on coverage decisions (also often termed ‘rationing’ or ‘priority setting’ decisions) and precisely on those decisions that employ the necessity criterion. In selecting the exact search terms, we aimed for results that included the articles retrieved and selected from the primary background search, for example [3,4,18]. For each of the three elements we included relevant thesaurus terms (Emtree terms for Embase and MeSH terms for Medline). We excluded conference papers, letters, notes and editorials, as well as articles written in any language other than English, but did not employ any date restrictions [19].

### 2.3. Selection and appraisal of documents

The first author (TKV) scanned titles, abstracts, and keywords in Endnote to include decisions that were made on the macro (government) or meso (local health authorities, sickness funds, and insurance companies) level [20]. BB, the last author, scanned a random subset of 537 studies. Together, an agreement rate of 96% was reached and further disagreement was resolved through discussion. This first round of inclusions amounted to a total of 666 studies. Next, TKV read all candidate papers in full and excluded 594 of the 666, ending up with 72 studies. Through snowballing, a




Fig. 1. Document flow diagram.

further 26 such studies were added, bringing the total number to 98 (see Fig. 1).

The inclusion criteria were: a) the article describes a hypothetical or actual coverage decision made concerning a specific form of care, treatment, therapy or medical technology, b) on the meso or macro level, and c) employing necessity-related considerations. We correspondingly excluded articles that: a) describe generalised criteria not applied to a specific form of care, b) concern ‘individual’ decisions (that is, for one patient) as they may concern the exception rather than the rule, and c) employ only effectiveness and/or cost-effectiveness or other quantitative argumentations. In doing so, we aimed to find studies containing concrete, qualitative, in-use argumentations that influence different types of coverage decisions as formulated by different actors on different levels regarding different forms of care.

#### 2.4. Data extraction

TKV extracted data from these 98 articles using Microsoft Excel and ATLAS.ti. During this process, ‘mode of agenda setting’ emerged as a potential context of influence. Conversely, ‘type of disease’ was removed as it proved unfruitful. To score the context, we noted country, year, macro- or meso level, and decision maker per identified argumentation, which was in turn scored as mechanism. The coverage decision was scored as the outcome, with eight outcome categories, of which three were used in case of an actual coverage decision:

‘Yes’: the treatment is unconditionally covered/conditions unspecified,

‘Conditional’: the treatment is covered for specific patient groups/indications,  
‘No’: the treatment is never covered.

Three categories were scored as hypothetical decisions (generally based on theory/interviews/surveys):

‘Should’: the treatment should be unconditionally covered/conditions unspecified,  
‘Should conditional’: the treatment should be covered for specific patient groups/indications,  
‘Should not’: the treatment should never be covered.

Furthermore, two categories were added later on to signify when an author or actor noted whether an argumentation should, or should not, have a bearing upon the decision.

‘Valid’: the consideration should be taken into account,  
‘Not valid’: the consideration should not be taken into account.

BB extracted data from a random subset of eleven studies, reaching an agreement rate of 73%, and full agreement was reached in deliberation.

#### 2.5. Analysis and synthesis process

Data analysis was undertaken by TKV, and candidate context-mechanism-outcome combinations were formulated according to the following pattern:

Based on these argumentation types, (mechanism) used in country C, put on the agenda by A, (contexts) lead to actual or hypothetical in- or exclusion of treatment T. (outcome)

Discussion with BB and AdB, the second reviewer, enabled the formulation of four meta-level theories.

### 3. Results

#### 3.1. Document characteristics

The 98 reviewed studies contain studies that are (in part) based on qualitative analyses of coverage decisions or policies (34 studies), interviews/surveys (26 studies), and case studies (twenty studies), but also ethical analyses (fourteen studies), opinion pieces (fourteen studies), economic analyses (eight studies), and reviews (seven studies), from over twenty (primarily Western) countries.

#### 3.2. Main findings

##### 3.2.1. General overview

In this paper, twenty argumentation types are described that are in use in hypothetical and actual coverage decisions. These twenty argumentation types are derived from over 400 argumentations found in 98 articles, for an overview of the argumentation types in alphabetical order, see Table 2.

The 98 reviewed articles are divided up into seven treatment sets (cancer therapies, orphan drugs, infertility treatments, Viagra, cosmetic surgery, obesity treatments and smoking cessation therapies). What follows is a detailed description of the use of these twenty argumentation types per treatment set in justifying positive, negative, and/or conditional coverage decisions, both actual and hypothetical. A handful of included articles is not described because there was too little information on that type of treatment: Alzheimer’s disease [21], genetic tests [22,23] and medical devices

**Table 2**

Overview of the twenty argumentation types that fall under the necessity criterion and their respective descriptions.

Argumentation type	Description
1) Definition of Illness	Whether the ailment is considered an illness for which treatment is necessary
2) Dignity	Whether (lack of) coverage is considered to affect the dignity of the patient to such an extent that it needs to be amended
3) Equity/Fairness/Justice	Whether coverage would be necessary to counter injustice/inequity/lack of fairness in (access to) treatment
4) Human Right	Whether (lack of) coverage is considered to affect the human rights of the patient to such an extent that it needs to be amended
5) Individual Cost	Whether lack of coverage would stop patients from buying necessary care themselves due to prohibitive cost
6) Individual Responsibility	Whether the individual is considered responsible for paying for this treatment
7) Medical Necessity	Whether or not a treatment is considered to be “medically necessary” or a “medical necessity”
8) Morbidity/Severity	Whether the physical and/or psychosocial morbidity associated with a certain ailment constitutes such a need that coverage is considered necessary
9) Moral Hazard	Whether there is considered to be a possibility of over-usage (i.e., unnecessary increase in demand, when people use more than they need as a result of coverage)
10) Need	The extent to which the patient is considered to be in need for which treatment is necessary
11) (No) Alternative	Whether or not viable alternatives are considered to be present which would make coverage more or less necessary
12) Patient-Diagnosis	Whether an illness is self-reported rather than diagnosed by a doctor
13) Range of Normality	Whether the experience of the patient is considered normal or abnormal to such an extent that coverage is deemed necessary
14) Rule of Rescue	Whether the identifiability of individuals close to death is considered to heighten the necessity of coverage
15) Similar Treatments	Whether similar treatments are covered or not (meaning that this <i>type</i> of treatment is considered necessary)
16) Small Number of Patients	Whether the small size of the patient population is considered to heighten the necessity of coverage (due to, amongst others, the inequality in terms of research expenditure or difficulties in obtaining high-quality data)
17) Societal Impact	Whether coverage is considered necessary to allay the impact this disease has on people beyond the patient
18) Societal Functioning	Whether coverage would aid a person's necessary functioning in society
19) Societal Responsibility	Whether society is considered responsible for paying for this treatment
20) Vulnerability/Compassion	Whether a compassionate response to vulnerable groups, e.g. children, in the form of coverage is considered to be a necessity

[24]. Notably, no new argumentation types are described in these articles.

### 3.2.2. Cancer therapies

For cancer therapies (Appendix Table 1 in Supplementary data), we observed solely positive coverage decisions. For these, higher incremental cost-effectiveness ratios than usual are acceptable [25], as evidenced by positive decisions made despite the fact that coverage would be inadvisable based on high cost [26], or “lack of clear clinical consensus about [a therapy's] benefits” [27]. Moreover, a few articles pose that “patients should be treated equally” regardless of the number of patients suffering from the specific type of cancer.

The main argumentation visible in this data subset poses that the need of the patient and the severity of the disease should be taken into account [28–32]. As cancer patients have urgent needs and a serious health condition, therefore therapy is, or should be, covered [26–28,30,33–37], heightened by concerns over dignity and impact on daily activities and family [31]. The Rule of Rescue is the main argumentation, where the necessity of covering a certain treatment is high specifically for identifiable patients who are in a life-threatening situation and are without alternative [33,36,38]. The unavailability of alternative treatments/therapies should thus be considered [27–29,37,39], as visible in several coverage decisions [25–29,34,36,37,39], but this argumentation is also sometimes questioned [28,33]. The ‘identifiable individuals’ element is also present in the ‘Small Number of Patients’ argumentation, which several authors pose is important [28,31,32], and as heightening justifiability [25,37], although others deny this [28,29,36]. The third main argumentation holds that for some, like children, exceptions are [30,39], may [28,31], may not [29], or

should be made [33]. This is expanded by Brock, who argues that those who have had fewest QALYs in their lifetime are the worst off, which is most obviously the case for paediatric patients [33]. The final argumentation concerns the distribution of health care resources [26,35]. E.g., Foy et al. emphasise that patients in different districts should be treated equally, thus arguing for more distributive justice [40].

### 3.2.3. Orphan drugs

For orphan drugs (Appendix Table 2 in Supplementary data), we identified argumentations for both positive and negative coverage decisions. The structure and types of argumentations of positive decisions in this data subset greatly resemble those for cancer therapies, and the use of a number of argumentations is questioned here as well.

Higher incremental cost-effectiveness ratios are generally found acceptable for orphan drugs, so decisions reek of making exceptions to this rule. The fact that the severity of the illness does or should count as an argumentation is stressed by many [2,41–50], and so is need [42,50]. Consequently, argumentations in favour of coverage include that orphan diseases are severe [44,51–53], that coverage only happens when they are [2] and/or when patients are in need [54]. Patients are said to be vulnerable, which should be [48,52], and is [54,55], considered, and to score low on societal functioning, and orphan drugs should be covered because they maintain or restore these capacities [52]. As for cancer therapies, a common argumentation supportive of provision is that patients have “no alternative” [51,53,56], often generally considered important [42,43,46,49]. The Rule of Rescue argues in favour of coverage in two cases [2,55], its relevance as a consideration is underlined by some [41,46,49], but also regularly questioned [1,47,52,57–60].



The small patient population is mentioned as an argumentation separately as well, but primarily to say it should not be of effect on the coverage decision [1,45,51,53,57,59–62], though not always [44,49,50]. Finally, the societal impact of treatment should be considered [49]. A new main argumentation in favour of coverage holds that the budget impact remains “sufficiently insignificant” given the low numbers of patients [59], as is the concurrent fact that the price is prohibitive to the individual [43]. “Equity” and distributive justice are once again mentioned but the exact line of reasoning is not always explicated [1,46,49,59], as is the case for the right to health care [59].

Arguing for denial of coverage, the most common assertion is that some orphan diseases may not be as severe as assumed, e.g. Gaucher's disease is said to be “minimally symptomatic” [2,58]. Hughes et al. state that orphan diseases may not “pose *sufficient imminent threat* to the life of patients to constitute a right to treatment” (italics mine) [59], see also [60]. One coverage decision cites “equity” as a reason [46]. Finally, denial of coverage for similar treatments may support another negative coverage decision [1,48].

### 3.2.4. Infertility treatments

The infertility treatment data subset was the largest and the most diverse, containing positive coverage decisions, including those that set indication criteria, as well as negative coverage decisions (Appendix Table 3 in Supplementary data).

The first main argumentation favouring coverage is that those seeking infertility treatment are in need [63–68], resulting in a positive coverage decision once [68]. Further, they are suffering morbidity [64,68–72], explicated as mental distress and psychological harm in decisions by UK health authorities [68]. Treatment may be medically necessary [73], and patients therefore deserve compassion [73,74]. The main argumentation holds that the “cost of [coverage of] assisted conception would be surprisingly small to the NHS as a whole, although to an individual it is often prohibitive” [72] and [70,71,75]. Thirdly, equity is mentioned again, but the underlying line of reasoning is more clearly explicated here, though not used in actual decisions. Lack of geographical equity as well as equity over the rich-poor divide is cause for concern [64,66,68,69,71–75]. Postcode and financial status should not affect coverage, and it would therefore be preferable to cover infertility treatment everywhere. Moreover, it is deemed inequitable to withhold treatment based on the environmental impact of having a child [76]. The fourth and main argumentations are not visible in the first two datasets, and both are only in use in hypothetical decisions, made by authors, patients and the general public. The fourth holds that infertility, or subfertility [71], is an illness and its cure should therefore be covered [65–74,76–79], especially because similar services are covered [71,72,76]. Fifthly, parenthood is part of the “right to reproduce” [74] or right to health [79], required for societal functioning [65,68,70,72,77,79], and part of “the basic opportunities every human should have” [67], also [63], and that those without children suffer stigmatisation [70,72], and their dignity is impacted [71]. Lastly, the societal impact of children, in economic terms, should be considered [80].

For the negative coverage decisions we observe main argumentations, of which some are new. First, infertility is not an illness, and therefore not covered [68,77], or should not be [76], also because it is not life-threatening [77]. In some cases, it is only covered in case of a diagnosed cause [66,69]. Other needs are thought “more pressing” [13,71], the treatment risky and not medically necessary [71], also the reason for exclusion from coverage in Ontario [74]. Infertility has little emotional appeal [71] and its treatment should therefore fall to personal, and not societal, responsibility [63,71,78]. Other argumentations that support a hypothetical negative coverage decision include potential moral hazard [63,77,79], and that

alternatives are available [73,76], of which the latter also used in an actual decision [13].

For the decisions that set indication criteria; Mladovsky and Sorenson describe how the necessity of coverage is lowered when doctors rely “on patients to ascribe infertility” [79]. Argumentations with concrete, micro-level indication criteria include, for example, “the number of children living in the home/from previous relationships” [64,66,69,78].

### 3.2.5. Viagra

Viagra is almost never covered [4,81], and moreover, about half of the argumentations oppose coverage (see Appendix Table 4 in Supplementary data). The other half contains both positive decisions and those that set indication criteria.

Viagra is, in actual coverage decisions, considered not medically necessary [4,81], patients not in need [81], and erectile dysfunction not serious enough to prevent societal functioning [18], or to be a normal part of ageing [4]. Moreover, the apparent subjectivity of this determination of need by the patient (rather than the doctor) may have further loosened the concept of ‘medical necessity’ for Viagra. This may well effectuate over-usage, as policy makers feel patients cannot be fully relied upon to make this kind of decision [81]. Moreover, because Viagra is available “over-the-web,” the doctor is thus conclusively unneeded for diagnosis and prescription, which decreases the necessity of coverage, further strengthened by fear of moral hazard [81].

Others, primarily authors, do support coverage of Viagra, based on the severity of psychosocial problems [81–83], impeded societal functioning as sexual function is considered essential to quality of life [82] and positive coverage of similar treatments [82].

Indication criteria are set in several countries, generally holding that Viagra as a treatment for erectile dysfunction is covered in cases of a spinal cord injury only, an argumentation related to the definition of illness and morbidity [4,81,83]. This use of the definition of illness argumentation is also questioned once [83].

### 3.2.6. Cosmetic surgery

Both the public and policy makers often regard cosmetic surgical procedures like tattoo removal or ‘boob jobs’ a prime example of a form of care that should not be funded [20,84]; in several countries it is indeed excluded from coverage [85]. The decisions examined all set limits on eligibility through indication criteria or, in cases like circumcision, exclude the form of care altogether.

The main argumentation offered in support of a decision setting indication criteria, that is, cosmetic surgery is generally reimbursed for certain indications only (see Appendix Table 5 in Supplementary data). All decisions, which included primarily actual and a few hypothetical decisions, use certain physical characteristics, evidence of physical or psychosocial morbidity, reduced social capacity, or a combination thereof, to argue for necessity of coverage in *certain cases*. Decision makers thus set physical or psychological patient eligibility criteria on the morbidity experienced that need to be applied by a physician [84,86–100]. Individual assessment providing evidence of morbidity here leads to a higher justifiability of surgery. In this way, surgery is performed only on those patients that fall on the ‘right’ side of the line between cosmetic and non-cosmetic care [86,100], or outside a “range of normality” [84,87–89,91,92,95–97,100–102], so that care is only provided if medically necessary [94,103]. Some argue that cosmetic surgery should be covered only in case of societal functioning problems [87,89,95], which McClean argues to be affected only in some cases [92]. Directly related is the illness definition [97,99]: what counts as illness needs treatment and what falls inside the ‘range of normality’ does not need treatment.

This is also reflected in the argumentation supporting a negative coverage decision, stating that because “newborns do not have a

medical condition,” circumcision should not be covered [99], see also [86,104]. Other argumentations against coverage include, for actual decisions, the availability of alternative treatments [103] and the lack of medical necessity [92], the latter also in hypothetical decisions [99,104,105].

Argumentations for a hypothetical positive decision were offered primarily for treatment of port-wine stains, with medical complications and psychosocial morbidity explicated [92], also [89]. The (potential of a) ‘postcode lottery’ was brought up a number of times, to apparently argue in favour of coverage [89,95,97,98,100].

### 3.2.7. Obesity treatments

Obesity treatments (Appendix Table 6 in Supplementary data) are often excluded from coverage [20]. However, various argumentations in support of coverage are visible in the literature, and a few in combination with indication criteria. In some cases, argumentations against coverage are given, but there is no evidence of public outrage over these negative decisions [106–109].

Articles mention the psychosocial burden of obesity [107,108] as supporting hypothetical coverage decisions, as well as the fact patients should be enabled to “conform to societal standards,” which is linked to the range of normality mentioned for cosmetic surgery. For actual decisions, potential co-morbidities [108], as well as the lack of alternatives and simply “need and solidarity principles” [108] are brought up. Further hypothetical argumentations favouring coverage include societal responsibility for these patients [106], “fair treatment” [107], consideration of “human dignity,” [108] and “social justice” [106].

Clear argumentations in support of decisions that set indication criteria are visible in decisions by American insurance companies, with positive decisions based on an expert opinion [107], the medical necessity as judged by a doctor [109] or a health risk assessment [106].

Conversely, the argumentations opposing coverage used by insurance companies in the USA hold that the individual patient is “to blame,” and that obesity treatment should therefore not be included [106,107], but also that obesity is not an illness [107] or not severe enough [109].

### 3.2.8. Smoking cessation therapies

Smoking cessation therapy (see Appendix Table 7 in Supplementary data) is covered in countries such as Australia, Canada, England, and the USA, though not in Argentina [110], and it has been included and excluded several times in the Netherlands [111]. The subset contains negative and positive coverage decisions, and focuses on the question of societal versus individual responsibility, only observed once before (in the obesity treatment subset).

For negative coverage decisions, main argumentations were elucidated. Firstly, smoking, or the cessation of it, is considered in actual decisions to be a “personal” issue [112,113]. Secondly, “tobacco consumption [is] not understood as an addiction or illness,” which reduces the necessity of coverage.

For positive coverage decisions, the main argumentations include firstly, for actual decisions, the obligation to attempt “safeguarding the wellbeing of fund participants” [112]. Secondly, for hypothetical decisions, it is argued that distributive rather than retributive justice ought to prevail [113]. Thirdly, addiction is an illness [113,114], also in use in actual decisions [111]. The fourth, though only used in hypothetical decisions, simply underlines the “need” for, or “necessity” of, smoking cessation services [110,112,113,115].

The Dutch policy for coverage of smoking cessation therapy deserves special attention [111]. Smoking cessation therapy was excluded supported by the argumentation that the costs “could

easily be paid from the savings that quitting smoking produced for individuals.”

### 3.3. Analysis

In order to identify context-mechanism-outcome patterns [12], we classified the twenty argumentation types per decision outcome: positive, negative and conditional coverage (Table 3). First, seven argumentation types are generally used in the justification of positive coverage decisions (both hypothetical and actual), namely: Equity/Fairness/Justice, Societal Functioning, Individual Cost, the coverage of Similar Treatments, Human Rights, Dignity and Societal Impact. Second, five argumentation types are solely in use in the justification of negative coverage decisions (both hypothetical and actual): Medical Necessity, Individual Responsibility, Moral Hazard, Small Number of Patients, and Patient-Diagnosis. Finally, eight argumentation types are employed for all types of coverage decision outcomes. This set comprises of Morbidity/Severity, Range of Normality, Definition of Illness, Vulnerability/Compassion, Need, (No) Alternative, Societal Responsibility and the Rule of Rescue. Conditional coverage is, moreover, generally based on Morbidity/Severity, Definition of Illness, Range of Normality, Societal Functioning and Medical Necessity – doctors in these cases make the final individual coverage decision. From Table 3, we thus observe that nearly two-thirds of the argumentation types is in use for either positive or negative decisions, from which we conclude the **first meta-level theory**: different argumentation types are generally used for different decision outcomes.

Table 4 gives a précis of those decisions where policy makers made a coverage decision responding to a patient (representative), the media or the public, and it was explicitly analysed in the article as such. These actors were thus reported to be involved in setting the decision on the agenda, often reacting to a negative decision. We quickly detected that all coverage decisions in this table have a positive outcome. We first identified two decisions [1,35] that use an argumentation type, in both cases Equity/Fairness/Justice, which is generally used in positive decisions (as visible in Table 3), meaning that the positive outcome was to be expected from the argumentation type used. However, we also found five cases that employ argumentation types also sometimes used to justify negative decisions, but that had, in fact, also a positive outcome [1,2,38,92,111]. From this, we conclude that who set the decision on the agenda may have played a role in these cases. The **second meta-level theory** is therefore: when the public or a patient (representative) is recorded to have been involved in setting the decision agenda, regardless of the argumentation type used, the decision outcome is positive in this dataset. Indubitably, we would need a more extensive analysis of grey literature and media coverage to ‘prove’ this conclusively or to draw conclusions for unexamined coverage decision processes. It seems conceivable, however, that the working of the argumentation types depends upon the context. We conclude that an important context is who set the agenda; when a patient (representative), lobbyist, journalist or politician was recorded to be involved, the resulting decision was always positive.

For the latter two meta-level theories, we utilise the distinction between ‘actual’ and ‘hypothetical’ coverage decisions. Actual decisions are those made by policy makers and insurance companies, that is, they concern coverage policies and therefore directly affect patients’ access to medicine or therapy. Hypothetical decisions are those made by all other parties, which includes patients, authors (generalising, primarily ethicists and economists), the general public, and the media. We grouped the twenty necessity argumentation types into two broad categories, which are based on the type of decision (actual vs. hypothetical) they are used in. The categorisation is made as follows: the first category is argumentations used

**Table 3**

Articles containing argumentation types used to justify coverage decisions per treatments or therapies. 'Cancer' stands for cancer therapies, 'orphan' for orphan drugs, 'infertility' for infertility treatments, 'cosmetic' for cosmetic surgery, 'obesity' for obesity treatments and 'smoking' for smoking cessation therapies. NB: When a particular argumentation-outcome combination occurred only once, the cell is coloured light grey.

Mechanism Argumentation type	Outcome					
	POSITIVE COVERAGE		NEGATIVE COVERAGE		CONDITIONAL COVERAGE	
	Actual	Hypothetical	Actual	Hypothetical	Actual	Hypothetical
Equity/Fairness/ Justice		Cancer [35] Cosmetic [89, 95, 97, 98, 100] Infertility [64, 66, 68, 69, 71–76] Obesity [106, 107] Orphan [1, 59] Smoking [113]	Orphan [46]			
Societal Functioning	Infertility [68]	Cancer [31] Cosmetic [92, 89] Infertility [65, 70, 72, 77, 79] Obesity [107, 108] Orphan [52] Viagra [82]	Viagra [18]		Cosmetic [87, 95]	
Individual Cost		Infertility [71, 75] Orphan [43]	Smoking [111]			
Similar Treatments		Infertility [71, 72] Viagra [82]	Orphan [48]			
Human Right		Infertility [63, 74, 79]				
Dignity		Cancer [31] Obesity [108]				
Societal Impact		Cancer [31] Infertility [80]				
Medical Necessity		Smoking [110]	Cosmetic [92, 103] Infertility [74] Viagra [4, 81]	Cosmetic [99, 104, 105] Infertility [71] Obesity [107]	Obesity [109]	Cosmetic [94, 103]
Individual Responsibility			Infertility [78] Smoking [112]			
Moral Hazard				Infertility [73] Viagra [81]		
Small Number of Patients	Cancer [25]			Cancer [29] Orphan [45, 51] Viagra [81]		
Patient-Diagnosis						
Morbidity/Severity	Cancer [26, 35]	Cancer [30, 37]	Cosmetic [84, 86]	Cosmetic [98, 99]	Cosmetic [84, 87–89,	
	Infertility [68] Viagra [81]	Cosmetic [90, 92, 93] Infertility [64, 69–72] Obesity [107, 108] Orphan [44, 51–53] Viagra [82, 83]	Obesity [109] Viagra [3, 18, 81]	Infertility [71, 77] Orphan [2, 59]	91, 94–98, 100] Infertility [78] Orphan [2, 54] Viagra [81]	
Range of Normality		Cosmetic [92, 96] Infertility [67]	Viagra [4]	Cosmetic [99]	Cosmetic [84, 87–89, 95–98, 100–102] Infertility [64, 78]	Cosmetic [98]
Definition of Illness	Obesity [108] Smoking [111]	Infertility [67, 69, 71– 73, 76, 79] Smoking [114] Viagra [82]	Infertility [68, 77] Obesity [107, 109] Smoking [110]	Infertility [76]	Cosmetic [97] Infertility [66, 69] Obesity [107] Viagra [4, 81]	Cosmetic [99]
Vulnerability/ Compassion	Cancer [30, 39] Orphan [54, 55]	Cancer [33] Cosmetic [89] Infertility [73, 74] Orphan [48]	Cosmetic [89]	Infertility [71]		
Need	Cancer [34–36] Infertility [68] Obesity [108]	Cancer [27] Cosmetic [103] Infertility [64–67] Smoking [115]	Viagra [3]	Infertility [66, 71] Orphan [60]		
[No] Alternative	Cancer [25, 26, 39, 36] Obesity [108] Smoking [112]	Cancer [27, 28, 37] Infertility [76] Orphan [51, 53, 56]	Cosmetic [103] Infertility [66]	Infertility [76]		
Societal Responsibility		Obesity [106]	Infertility [71]	Infertility [71]		Smoking [124]
Rule of Rescue		Cancer [33, 36, 38] Orphan [2, 55]		Cancer [33] Orphan [52, 53, 57, 58]	Orphan [2]	

in both actual and hypothetical decisions, the second category contains argumentations *only* used in hypothetical decisions.

The first category (as visible in the upper half of Table 5) contains ten argumentation types: Definition of Illness, Individual Responsibility, Medical Necessity, Morbidity/Severity, Need, (No) Alternative, Range of Normality, Societal Functioning, Societal Responsibility and Vulnerability/Compassion. The lower half of Table 5 holds the second category of necessity argumentations, which are only used in hypothetical decisions. It consists of the following ten argumentation types: Dignity, Equity/Fairness/Justice, Human Rights, Individual Cost, Moral Hazard, Patient-Diagnosis,

Rule of Rescue, Similar Treatments, Small Number of Patients, and Societal Impact.

Furthermore, we observe that the first category contains the three most strongly acknowledged argumentation types, namely Morbidity/Severity (acknowledged thirteen times), (No) Alternative (eight times) and Need (seven times). In contrast, the second category holds the two most strongly questioned argumentations (that is, more than once), namely Small Number of Patients (questioned six times) and Rule of Rescue (four times), though these were also as often acknowledged as valid (seven times and five times, respectively).

**Table 4**

Overview of decisions where it was recorded that the public, a patient or a patient representative was involved in setting the coverage decision on the policy agenda, with the argumentation type and final decision.

Context		Mechanism	Outcome	Reference
Country	Actor	Argumentation type(s)	Decision	
UK	Politician	Equity/Fairness/Justice	Positive	[1]
Canada	Patient representative	Equity/Fairness/Justice	Positive	[35]
Canada	Patient representative	Rule of Rescue	Positive	[2]
Australia	Journalist	Rule of Rescue	Positive	[38]
		Small Number of Patients		
		No Alternative		
USA	Patient	Morbidity/Severity	Positive	[92]
		Medical Necessity		
		Societal Functioning		
UK	Patient	(not explicated, possibly Morbidity/Severity or Need)	Positive	[1]
Netherlands	Lobbyist	(not explicated, possibly Societal Responsibility or Societal Impact)	Positive	[111]

Based on this analysis, we formulate the **third meta-level theory**: half of the argumentation types are used by policy makers and insurance companies as well as patients, authors, the public and the media, whereas the other half are only used by the latter group. The argumentation types that are used by policy makers and insurance companies are, moreover, more frequently acknowledged as valid, whereas some that are only used by patients, authors, the public and the media are strongly questioned.

In an effort to understand whether and how the geographical location (the second context that we observed the impact of) affected the use of argumentation types, we plotted the usage frequency per country in Table 6. We identified the following parallels between the countries. From the first necessity category (the upper half of Table 6, categorised by use as described above), most countries employ most argumentation types at some point, and all countries employ the argumentation types Morbidity/Severity, (No) Alternative, and Vulnerability/Compassion. In contrast, Medical Necessity is restricted to the USA, and Need is most frequently visible for ‘mainland Europe’ (France, Germany, Sweden and the Netherlands). For the second necessity category (the lower half of Table 6), the pattern is much less congruent. Canada and Australia have the highest percentage of use of argumentations grouped into this category. Moreover, only these countries utilise the more controversial argumentation types, namely Rule of Rescue and Small Number of Patients, whereas this is not the case for the other countries. This is to be expected, as the Rule of Rescue is part of the official criteria of the PBAC, cf. [28]. In addition, the UK has a high percentage of the Equity/Fairness/Justice argumentation type, which is primarily due to the concern and outrage about ‘postcode rationing’ [87,89,95,97,98,100].

Accordingly, we formulated the **fourth and final meta-level theory**, which holds that the argumentations that fall under the first necessity category appear to be applied in most of the (predominantly Western) countries the dataset reports on, though the countries do appear to have their own argumentation type preferences. For the second category the patterns are much more varied: many argumentation types are have a specific pattern (that is, used in two or three countries), which we conclude as depending on the local context.

#### 4. Discussion

In this paper, we unpack the question of necessity of coverage by reviewing the argumentations used, and proposed to be used, in coverage decision making. In seven treatment sets (cancer therapies, orphan drugs, infertility treatments, Viagra, cosmetic surgery, obesity treatments and smoking cessation therapies) from 98 reviewed articles, we identified twenty different argumentation

types employed to argue for or against the necessity of coverage of a certain therapy or treatment.

The argumentation types may be typified by primary decision outcome. The following argumentation types are used primarily in favour of coverage: equity, fairness and justice, a patient's societal functioning being impeded, the cost being too high to bear for an individual, the coverage status of similar treatments, considerations concerning Human Rights and dignity of the patient, and wider societal impact. Reversely, limited medical necessity, the individual being held responsible, potential moral hazard or over-usage, a small patient population, and a doctor needing to rely on the patient to set the diagnosis are argumentations solely employed to decrease the necessity of coverage. Finally, the morbidity experienced or the severity of the disease, whether the ailment falls within a defined ‘range of normality’ or is considered an illness, compassion for vulnerable patients, the need of the patient, the (un)availability of alternatives, society having to take responsibility for coverage, and the Rule of Rescue are used both in favour of and opposing coverage. The most important context affecting the argumentations in use in coverage decisions is the way the decision has come onto the agenda: when this is recorded in the article to be by a patient, a patient organisation or the public, this always facilitates a positive decision in this dataset, even when the argumentation type employed is also in use in negative coverage decisions. Others have stressed much the same point [116]; in a cross-country comparison of hepatitis C coverage, Kieslich et al. describe experiences that are “as much a tale of challenges that arise when making difficult prioritization decisions as they are a tale of agenda-setting” [117]. Overall, it is important to note that no wide consensus is needed to let a consideration function as an argumentation in coverage decisions. This makes it doubly interesting to investigate what exactly happens during the processes of coverage decision making.

Necessity is also broadly categorised by two different types of usage. Under the first necessity category, indicating use in both actual and hypothetical decisions, fall the definition of illness and range of normality, the individual's own responsibility, the medical necessity, the morbidity (or the severity of the disease) and need experienced, the presence or absence of alternatives, the societal functioning of the patient, the societal responsibility for coverage and compassion towards vulnerable patients. The second necessity category is not used in actual coverage decisions, that is, by policy makers and insurance companies, but rather only by patients, authors, the public, the media, etc. For this second necessity category, we observed dignity, equity, fairness and justice considerations, human rights, the individual cost of the treatment, moral hazard, whether the patient sets the diagnosis him- or herself, the Rule of Rescue, coverage of similar treatments, the size of the patient population, and the societal impact of coverage. Inter-



**Table 5**

Twenty argumentation types organised per category, and the articles containing argumentations per treatment set per decision type of outcome (actual vs. hypothetical). 'Cancer' stands for cancer therapies, 'orphan' for orphan drugs, 'infertility' for infertility treatments, 'cosmetic' for cosmetic surgery, 'obesity' for obesity treatments and 'smoking' for smoking cessation therapies. NB: When a particular argumentation-outcome combination occurred only in one article, the cell is coloured light grey.

Mechanism		Outcome	
Argumentation type		Decision type	
		Actual decision [Policy makers and insurance companies]	Hypothetical decision [Patients, authors, the public and the media]
Used in both actual and hypothetical decisions	Definition of Illness	Cosmetic [97] Infertility [66, 68, 69, 77] Obesity [107, 108, 109] Smoking [110, 111] Viagra [4, 81]	Cosmetic [99] Infertility [67, 69, 71-73, 76, 79] Smoking [114] Viagra [82]
	Individual Responsibility	Infertility [78] Smoking [112]	Obesity [107]
	Medical Necessity	Cosmetic [92, 103] Infertility [74] Obesity [109] Viagra [4, 81]	Cosmetic [94, 99, 103-105] Infertility [71] Smoking [110]
	Morbidity/Severity	Cancer [26, 35] Cosmetic [84, 87-89, 91, 94-98, 100] Infertility [68, 78] Obesity [109] Orphan [2, 54] Viagra [3, 18, 81]	Cancer [30, 37] Cosmetic [90, 92, 93, 98, 99] Infertility [64, 69-72, 77] Obesity [107, 108] Orphan [2, 44, 51-53, 59] Viagra [82, 83]
	Need	Cancer [34-36] Infertility [68] Obesity [108] Viagra [3]	Cancer [27] Cosmetic [103] Infertility [64-67, 71] Orphan [60] Smoking [115]
	[No] Alternative	Cancer [25, 26, 39, 36] Cosmetic [103] Infertility [66] Obesity [108]	Cancer [27, 28, 37] Infertility [76] Orphan [51, 53, 56]
	Range of Normality	Cosmetic [84, 87-89, 95-98, 100-102] Infertility [64, 78] Viagra [4]	Cosmetic [92, 96, 98, 99] Infertility [67]
	Societal Functioning	Cosmetic [87, 95] Infertility [68] Viagra [18]	Cancer [31] Cosmetic [92, 89] Infertility [65, 70, 72, 77, 79] Obesity [107, 108] Orphan [52] Viagra [82]
	Societal Responsibility	Smoking [112] Infertility [71]	Infertility [71] Obesity [106] Smoking [124]
	Vulnerability/Compassion	Cancer [30, 39] Cosmetic [89] Orphan [54, 55]	Cancer [33] Cosmetic [89] Infertility [71, 73, 74] Orphan [48]

Table 5 (Continued)

Used in hypothetical decisions only	Dignity		Cancer [31] Obesity [108]
	Equity/Fairness/Justice	Orphan [46]	Cancer [35] Cosmetic [89, 95, 97, 98, 100] Infertility [64, 66, 68, 69, 71–76] Obesity [106, 107] Orphan [1, 59] Smoking [113]
	Human Rights		Infertility [63, 74, 79]
	Individual Cost	Smoking [111]	Infertility [71, 75] Orphan [43]
	Moral Hazard		Infertility [73] Viagra [81]
	Patient-Diagnosis		Viagra [81]
	Rule of Rescue	Orphan [2]	Cancer [33, 36, 38] Orphan [2, 52, 53, 55, 57, 58]
	Similar Treatments	Orphan [48]	Infertility [71, 72] Viagra [82]
	Small Number of Patients	Cancer [25]	Cancer [29] Orphan [45, 51]
	Societal Impact		Cancer [31] Infertility [80]

estingly, the use of the argumentation types that fall under this category is more localised, that is, country-specific, and more frequently debated. The argumentation types belonging to the first necessity category, however, are much more universally applied.

#### 4.1. Comparison with existing literature

Our search string yielded seven studies containing literature reviews that were included in our review [30,35,49,53,79,96,118], as well as a number of reviews that specified general qualitative criteria for coverage decisions. Cromwell, Peacock and Mitton have conducted a literature review of ‘real-world’ decision criteria as found in 33 articles in peer-reviewed and grey literature [119]. They searched for articles with an explicit acknowledgement of a “finite resource pool.” Therefore, their review focuses on resource allocation, i.e., choosing one thing over another, in different settings such as hospitals and health authorities. They found that disease impact (burden) was an influential criterion in resource allocation decisions, but did not observe other necessity-based argumentations.

Several other studies, e.g., Cerri et al., examined technology appraisals as conducted by macro-level institutions and commonly find it to be a “complex process involving numerous clinical, disease, and affordability considerations” [120]. Shah examined popular preferences in using severity of illness in economic evaluation as part of priority setting, showing that “people are, on the whole, willing to sacrifice aggregate health in order to give priority to the severely ill,” which may further legitimise the use of individual burden of disease as a coverage criterion [121]. Fischer conducted a broad review of decisions where quantitative methods were employed, and identified several clinical criteria that strengthen our conclusions: availability of treatment alternative; condition is life threatening; condition caused by patients own behaviour; and end of life considerations [122]. Hasman, McIntosh and Hope, finally, interviewed decision makers on what they considered relevant in a coverage decision on a hypothetical drug [123]. The interviews highlighted agreement over cost effectiveness, clinical effectiveness, equality and gross cost as important reasons for coverage. Interestingly, a lack of agreement was elicited over using ‘absence of alternative treatments’ as a criterion. Our study, rather than aiming to outline general criteria in use in coverage decisions, specifically gives an analysis of the tonal variety in the use of necessity in actual and hypothetical coverage decisions, and the effect contexts may have on the final coverage decision.

ical effectiveness, equality and gross cost as important reasons for coverage. Interestingly, a lack of agreement was elicited over using ‘absence of alternative treatments’ as a criterion. Our study, rather than aiming to outline general criteria in use in coverage decisions, specifically gives an analysis of the tonal variety in the use of necessity in actual and hypothetical coverage decisions, and the effect contexts may have on the final coverage decision.

#### 4.2. Strengths, limitations and future research directions

To study, like we have, the way contexts influence coverage decision outcomes through the use of necessity as a criterion will aid our understanding of both coverage decision making as well as necessity as a concept as used in practice. In addition, the wide variety of argumentations described will aid further ethical reflection on the content and processes of actual and hypothetical coverage decisions.

Our search strategy in particular provided a challenge, as when one searches for “need” in the title/abstract, the articles that will be found are likely to discuss coverage decisions that use “need” as a criterion. As such, certain necessity-based argumentations were in that sense already to be expected from the wording of the search strategy. We have engaged two expert librarians to aid us in order to widen and strengthen our search terms and have thus acquired a relatively ‘broad but clean’ dataset.

The use of the realist review method has sharpened our review by forcing us to both broaden our choice in articles (opinion pieces, ethical and economic analyses and reviews were analysed on top of document analyses and interviews/surveys) and take the defined contexts, rather than the practical set-up of the research, as primary quality attribute for inclusion and scoring. Although not always easy to accomplish, this study shows that the realist review method may successfully be applied to a wider variety of interventions than classical policy interventions such as patient portals [10] or internet-based medical education [124]. Necessity as a criterion is a policy ‘product’ that interacts with a variety of contexts to pro-

**Table 6**

Percentages of use of argumentation types per country (for which a minimum of five argumentations was found). The argumentation types are shown in alphabetical order per category. Human Rights and Patient-Diagnosis are absent as they were not used in country-specific argumentations.

Mechanism		Context				
Argumentation type		Australia	Canada	USA	UK	France, Germany, Sweden, the Netherlands
<i>Used in both actual and hypothetical decisions</i>	Definition of Illness	-	4.9	19.2	5.6	13.5
	Individual Responsibility	-	-	5.8	1.1	-
	Medical Necessity	-	4.9	19.2	-	2.7
	Morbidity/Severity	25.0	19.5	19.2	28.1	16.2
	Need	-	7.3	5.8	7.9	18.9
	(No) Alternatives	25.0	12.2	5.8	7.9	16.2
	Range of Normality	-	-	7.7	16.9	5.4
	Societal Functioning	-	2.4	3.8	5.6	2.7
	Societal Responsibility	-	-	1.9	-	2.7
	Vulnerability/Compassion	16.7	12.2	3.8	4.5	10.8
<i>Used in hypothetical decisions only</i>	Equity/Fairness/Justice	-	7.3	5.8	13.5	-
	Dignity	-	2.4	-	-	2.7
	Individual Cost	-	-	-	-	2.7
	Moral Hazard	-	-	1.9	-	-
	Rule of Rescue	25.0	12.2	-	1.1	-
	Similar Treatments	-	2.4	-	2.2	-
	Small Number of Patients	8.3	9.8	-	5.6	5.4
	Societal Impact	-	2.4	-	-	-
Total number of argumentations		12	41	52	89	37

duce certain outcomes, and to frame our question thus has elicited exciting data on the varied use of necessity as a criterion in coverage decisions from peer-reviewed literature. It must, however, also be stressed that we have not effectuated a different ‘weighing’ of actual versus hypothetical decisions, and that ethical discussions and public attitude surveys are of a wholly different substance than coverage decisions made by policy makers as they directly affect patients’ lives. The inclusion of hypothetical decisions has not been self-evident, but it has been crucial to giving an overview of as wide a selection of criteria-in-action as possible.

It is, however, debatable to what extent we have grasped the full context of these criteria-in-action due to the way ‘context’ has been defined in this study. For example, on the micro level in Sweden, despite the national-level guidance not to treat smokers differently, “physicians are more inclined to treat a non-smoking patient” [125]. The element of weighing personal responsibility in coverage decisions is visible here, but rarely expressed as such in health policy [126]. This shows that criteria may be exhibited in other argumentations at the bedside, (e.g., [87,127]), or in court (e.g., [13,128]). We have also omitted the characteristics of the exact form of care under consideration as being potentially influential, insofar as they were not described as part of the argu-

mentations (cf. Lowi in [117]). Additionally, one could argue that the way contexts have been defined in this study obscures the role of the decision maker or the structure of the decision making process, as these also have not been considered as ‘contexts’. Furthermore, the ‘agenda setting’ context is a short consideration of decisions that may have been made for political, rather than explicitly patient-focused, reasons [110,111,129]. Lastly, the data contained few articles on non-Western countries, which, upon becoming available, may well nuance the homogeneity in use of necessity considerations between countries. This, as well as additional research on the contexts mentioned earlier, may prove fruitful lines of further inquiry.

Finally, it would appear that using the realist review method predisposes one to think in terms of causality: a certain mechanism in a certain context leads to a certain outcome; argumentation type M, when used in country C leads to (hypothetical or actual) inclusion of treatment T. This, in itself, is problematic: the fact that a combination occurred ‘out there’ does not necessarily mean it *needed* to happen that way; it underplays the agency of the decision makers in this important sense. It also assumes that the outcome ‘comes last’; it leaves no space for (additional) justifications that may have been brought in after the decision was made. Further

investigation, for example through an ethnography, of the coverage decision making process and the role and use of necessity as a criterion in coverage decisions would be a useful exercise to shed more light hereon.

## 5. Conclusion

Necessity as a criterion in coverage decisions has lacked operationalisation: this paper provides a handle on the wide variety of argumentation types that fall under this umbrella term by reviewing over 400 argumentations described in 98 peer-reviewed articles. These argumentations are grouped into twenty different necessity-based argumentation types that are used in coverage decisions, both 'actual' decisions (made by policy makers and insurance companies) as well as 'hypothetical' decisions (made by actors such as patients, authors, the public and the media).

Eight of these twenty necessity-based argumentation types are used to support both positive and negative coverage decisions; twelve are however only employed for either positive or negative decisions. When patients or the public was recorded to have aided in setting the decision on the agenda, this always resulted in a positive decision, even when an argumentation type was used that could have resulted in a negative decision.

The argumentation types heightening or lowering necessity of coverage of a certain form of care may also be distinguished by their users. Half of the argumentation types is used in both actual and hypothetical coverage decisions, that is, by policy makers and insurance companies as well as patients, authors, the public and the media. The second half is, in contrast, only used by the latter group. Argumentation types used in actual as well as hypothetical decisions are more strongly acknowledged and used in a greater number of countries. Conversely, argumentation types used in hypothetical decisions only are more strongly questioned, and their use is more country-specific.

## Conflict of interest

We wish to draw the attention of the Editor-in-Chief to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Zorginstituut Nederland (Dutch Health Care Institute) [grant number 22070000.999.015].

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). She is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author.

## Acknowledgements

We would first like to thank our colleagues at the Health Care Governance section for a thoroughly fruitful discussion of a very

early draft. Second, we are grateful to the International Society on Priorities in Health for the opportunity to present this paper at its 11th biennial meeting in Birmingham, United Kingdom. Third, we acknowledge Wichor Bramer, information specialist at the Erasmus Medical Centre, Rotterdam, for his extensive help with the search string, deduplication of the search results and aid in navigating Endnote. Last but not least, we are indebted to two anonymous reviewers for their generous and helpful comments.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.healthpol.2017.04.011>.

## References

- [1] Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. *BMJ* 2005;331(7523):1019–21.
- [2] Clarke JTR, Amato D, Deber RB. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. *CMAJ: Canadian Medical Association Journal* 2001;165(5):595–6. PubMed PMID: PMC81418.
- [3] Bernfort L. Decisions on inclusion in the Swedish basic health care package—roles of cost-effectiveness and need. *Health Care Analysis* 2003;11(4):301–8.
- [4] Stolk EA, Brouwer WBF, Busschbach JJV. Rationalising rationing: economic and other considerations in the debate about funding of Viagra. *Health Policy* 2002;59(1):53–63.
- [5] Ham C. Priority setting in health care: learning from international experience. *Health Policy* 1997;42(1):49–66.
- [6] Mitton C, Smith N, Peacock S, Evoy B, Abelson J. Public participation in health care priority setting: a scoping review. *Health Policy* 2009;91(3):219–28.
- [7] Martin DK, Giacomini M, Singer PA. Fairness, accountability for reasonableness, and the views of priority setting decision-makers. *Health policy* 2002;61(3):279–90.
- [8] Kipiriri L, Norheim OF, Martin DK. Fairness and accountability for reasonableness. Do the views of priority setting decision makers differ across health systems and levels of decision making? *Social Science & Medicine* 2009;68(4):766–73.
- [9] Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: realist syntheses. *BMC Medicine* 2013;11(1):1.
- [10] Otte-Trojel T, de Bont A, Rundall TG, van de Klundert J. How outcomes are achieved through patient portals: a realist review. *Journal of the American Medical Informatics Association* 2014;21(4):751–7.
- [11] Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol-realist and meta-narrative evidence synthesis: evolving standards (RAMESES). *BMC Medical Research Methodology* 2011;11(1):115.
- [12] Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review—a new method of systematic review designed for complex policy interventions. *Journal of Health Services Research & Policy* 2005;10(Suppl. 1):21–34.
- [13] Giacomini M. One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions. *Milbank Quarterly* 2005;83(2):193–223.
- [14] Akhmetov I, Bubnov RV. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. *EPMA Journal* 2015;6(1).
- [15] Couwenbergh B, van der Meer F, Weghaus-Reus S, Schelleman H, Zwaap J. Pakketbeheer in de praktijk deel 3. Diemen: Zorginstituut Nederland; 2013. p. 1–106.
- [16] Bramer W, Holland L, Mollema J, Hannon T, Bekhuis T. Removing duplicates in retrieval sets from electronic databases: Comparing the efficiency and accuracy of the Bramer-method with other methods and software packages; 2014.
- [17] Bramer WM, Kleijnen J, Oscar O.H. Franco Optimal database combinations for systematic review searches. Submitted for publication.
- [18] Hoedemaekers R, Oortwijn W. Problematic notions in Dutch health care package decisions. *Health Care Analysis* 2003;11(4):287–94.
- [19] Bramer WM, Rethlefsen ML, Mast F, Kleijnen F. A systematic approach to searching: An efficient and complete method to develop literature searches. Submitted for publication.
- [20] Polikowski M, Santos-Eggimann B. How comprehensive are the basic packages of health services? An international comparison of six health insurance systems. *Journal of Health Services Research & Policy* 2002;7(3):133–42.
- [21] Bernardi A, Pegoraro R. Italian drug policy: ethical aims of essential assistance levels. *Health Care Analysis* 2003;11(December (4)):279–86. PubMed PMID: 14769009.
- [22] Fischer KE, Rogowski WH. Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe. *International Journal of Environmental Research and Public Health* 2014;11(May (5)):5403–30. PubMed PMID: WOS:000337251900050. English.



- [23] Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. *JNCCN Journal of the National Comprehensive Cancer Network* 2015;13(3):311–8.
- [24] Kissler A, Tüchler H, Erdös J, Wild C. Factors influencing coverage decisions on medical devices: a retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015. *Health Policy* 2016;120(8):903–12.
- [25] Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of Sunitinib for first-line treatment of metastatic renal cell carcinoma. *Value Health* 2010;13(6):837–45.
- [26] Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. *Journal of Clinical Oncology* 2007;25(2):191–5.
- [27] Daniels N, Sabin JE. Last chance therapies and managed care Pluralism, fair procedures, and legitimacy. *Hastings Center Report* 1998;28(2):27–41.
- [28] Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. *Journal of Medical Ethics* 2008;34(7):540–4.
- [29] Linley WG, Hughes DA. Societal views on nice, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. *Health Economics* 2013;22(8):948–64.
- [30] Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. *Value Health* 2008;11(July–August (4)):771–83. PubMed PMID: WOS:000258144900025. English.
- [31] Stafinski T, McCabe C, Menon D. Determining social values for resource allocation decision-making in cancer care: a Canadian experiment. *Journal of Cancer Policy* 2014;2(3):81–8.
- [32] Trowman R, Chung H, Longson C, Littlejohns P, Clark P. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales. *Clinical Cancer Research* 2011;17(15):4930–5.
- [33] Brock DW. Ethical and value issues in insurance coverage for cancer treatment. *Oncologist* 2010;15(Suppl. 1):36–42.
- [34] Martin DK, Pater JL, Singer PA. Priority-setting decisions for new cancer drugs: a qualitative case study. *Lancet* 2001;358(November (9294)):1676–81. PubMed PMID: WOS 000172344100010. English.
- [35] Aggarwal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: what informs the debate? Perspectives from the EU, Canada and US. *Journal of Cancer Policy* 2014;2(1):1–11.
- [36] Singer PA, Martin DK, Giacomini M, Purdy L. Priority setting for new technologies in medicine: qualitative case study. *BMJ* 2000;321(7272):1316–8.
- [37] Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases—a case study in oncology. *Journal of Clinical Pharmacology* 2009;16(2):e273–81, discussion e82–4. PubMed PMID: 19439771. eng.
- [38] MacKenzie R, Chapman S, Salkeld G, Holding S. Media influence on Herceptin subsidization in Australia: application of the rule of rescue? *Journal of the Royal Society of Medicine* 2008;101(June (6)):305–12.
- [39] Lim CS, Lee YG, Koh Y, Heo DS. International comparison of the factors influencing reimbursement of targeted anti-cancer drugs. *BMC Health Services Research* 2014. Nov;14 PubMed PMID: WOS:000347348400001. English.
- [40] Foy R, So J, Rous E, Scarffe JH. Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. *BMJ* 1999;318(7181):456–9.
- [41] Bae G, Bae EY, Bae S. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea. *Health Policy* 2015;119(May (5)):577–87. PubMed PMID: WOS 000355031900003. English.
- [42] Cohen JP, Felix A. Are payers treating orphan drugs differently? *Journal of Market Access & Health Policy* 2014;2(1):23513, <http://dx.doi.org/10.3402/jmahp.v2.23513>, 01/15/05/accepted;2:10.3402/jmahp.v2.23513. PubMed PMID: PMC4865792.
- [43] Denis A, Mergaert L, Fostier C, Cleemput I, Hulstaert F, Simoons S. Critical assessment of Belgian reimbursement dossiers of orphan drugs. *Pharmacoconomics* 2011;29(10):883–93.
- [44] Hughes D. Rationing of drugs for rare diseases. *Pharmacoeconomics* 2006;24(4):315–6.
- [45] Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. *Health Economics, Policy, and Law* 2011;6(3):405–33.
- [46] Rosenberg-Yunger ZRS, Daar AS, Thorsteinsdóttir H, Martin DK. Priority setting for orphan drugs: an international comparison. *Health Policy* 2011;100(1):25–34.
- [47] Schlender M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. *Current Medical Research and Opinion* 2009;25(May (5)):1285–93. PubMed PMID: 19366306.
- [48] Winquist E, Bell CM, Clarke JT, Evans G, Martin J, Sabharwal M, et al. An evaluation framework for funding drugs for rare diseases. *Value Health* 2012;15(September–October (6)):982–6. PubMed PMID: 22999151.
- [49] Zelei T, Molnár MJ, Szegedi M, Kaló Z. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. *Orphanet Journal of Rare Diseases* 2016;11(1):72.
- [50] Nicod E. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries. *The European Journal of Health Economics* 2016;1–16.
- [51] Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. *The European Journal of Health Economics* 2014;15(4):335–40.
- [52] Largent EA, Pearson SD. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. *Hastings Center Report* 2012;42(January–February (1)):27–34. PubMed PMID: 22616398.
- [53] Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. *Pharmacoeconomics* 2015;33.
- [54] Henschke C. Provision and financing of assistive technology devices in Germany: a bureaucratic odyssey? The case of amyotrophic lateral sclerosis and Duchenne muscular dystrophy. *Health Policy* 2012;105(2–3):176–84.
- [55] Bañón Hernández Antonio A, Solves Almela J. The debate on rare diseases: a look at media response. *Métode Science Studies Journal: Annual Review* 2015;0(6), eng.
- [56] Iskrov GG, Raycheva RD, Stefanov RS. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs. *Folia Medica (Plovdiv)* 2013;55(3–4):80–6.
- [57] Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. *BMJ* 2010;341:c4715.
- [58] Gross ML. Ethics, policy, and rare genetic disorders: the case of gaucher disease in Israel. *Theoretical Medicine and Bioethics* 2002;23(2):151–70.
- [59] Hughes D, Tunnage B, Yeo S. Drugs for exceptionally rare diseases: do they deserve special status for funding? *QJM* 2005;98(11):829–36.
- [60] Juth N. For the sake of justice: should we prioritize rare diseases. *Health Care Analysis* 2014;1–20.
- [61] Desser AS. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. *Social Science & Medicine* 2013;94.
- [62] McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: Should we value rarity? *British Medical Journal* 2005;331.
- [63] Blank RH. Assisted reproduction and reproductive rights: the case of in vitro fertilization. *Politics Life Sciences* 1997;16(September (2)):279–88. PubMed PMID: 11902211.
- [64] Shaw LMA, Balen A, Lenton E, Brown C, Greenwood B. National health service provision for the management of infertility: the case for funding and reorganization of fertility services in the UK. *Human Fertility* 2002;5(4):167–74.
- [65] McMillan J. Allocating fertility services by medical need. *Human Fertility* 2001;4(1):11–3, 2001/01/01.
- [66] McWhirter M, McQueen D. Rationing and NHS fertility services: a commissioning perspective. *Human Fertility* 2000;3(4):271–4.
- [67] Rauprich O, Berns E, Vollmann J. Who should pay for assisted reproductive techniques? Answers from patients, professionals and the general public in Germany. *Human Reproduction* 2010;(March).
- [68] Redmayne S, Klein R. Rationing in practice: the case of in vitro fertilisation. *British Medical Journal* 1993;306(6891):1521–4.
- [69] Brown CJ. Rationing fertility services in the NHS: the patients' viewpoint. *Human Fertility* 2000;3(4):268–70.
- [70] Chambers GM, Adamson GD, Eijkemans MJC. Acceptable cost for the patient and society. *Fertility and Sterility* 2013;100(2):319–27.
- [71] Hughes EG, Giacomini M. Funding in vitro fertilization treatment for persistent subfertility: the pain and the politics. *Fertility and Sterility* 2001;76(September (3)):431–42. PubMed PMID: WOS 000170863300001. English.
- [72] Lord J, Shaw L, Dobbs F, Acharya U. A time for change and a time for equality—infertility services and the NHS. *Human Fertility* 2001;4(4):256–60.
- [73] Nachtigall RD, MacDougall K, Davis AC, Beyene Y. Expensive but worth it: older parents' attitudes and opinions about the costs and insurance coverage for in vitro fertilization. *Fertility and Sterility* 2012;97(January (1)):82–7. PubMed PMID: WOS:000298367600018. English.
- [74] Giacomini M, Hurley J, Stoddart G. The many meanings of deinsuring a health service: the case of in vitro fertilization in Ontario. *Social Science & Medicine* 2000;50(10):1485–500.
- [75] Chambers GM, Ho MT, Sullivan EA. Assisted reproductive technology treatment costs of a live birth: an age-stratified cost-outcome study of treatment in Australia. *Medical Journal of Australia* 2006;184(February (4)):155–8. PubMed PMID: 16489897.
- [76] Wilkinson S, Williams NJ. Should uterus transplants be publicly funded? *Journal of Medical Ethics* 2016;42:559–65.
- [77] Neumann PJ. Should health insurance cover IVF? Issues and options. *Journal of Health Politics, Policy and Law* 1997;22(5):1215–39.
- [78] Plomer A, Smith I, Martin-Clement N. Rationing policies on access to in vitro fertilisation in the National Health Service, UK. *Reprod Health Matters* 1999;7(14):60–70.
- [79] Mladovsky P, Sorenson C. Public financing of IVF: a review of policy rationales. *Health Care Analysis* 2010;18(2):113–28.
- [80] Connolly MP, Ledger W, Postma MJ. Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms. *Human Fertility* 2010;13(1):13–8. PubMed PMID: WOS:000291426100002. English.
- [81] Klein R, Sturm H. Viagra a success story for rationing? *Health Affairs (Millwood)* 2002;21(November–December (6)):177–87. PubMed PMID: 12442853.

- [82] Hornbrook MC, Holup J. Insurance coverage for erectile dysfunction drugs. *Clinical Pharmacology & Therapeutics* 2011;89(1):19–21.
- [83] Manson H. The role of the 'lifestyle' label and negative bias in the allocation of health resources for erectile dysfunction drugs: an ethics-based appraisal. *International Journal of Impotence Research* 2005;18(1):98–103.
- [84] Russell J, Swinglehurst D, Greenhalgh T. 'Cosmetic boob jobs' or evidence-based breast surgery: an interpretive policy analysis of the rationing of 'low value' treatments in the English National Health Service. *BMC Health Services Research* 2014;14:413.
- [85] Schreyögg J, Stargardt T, Velasco-Garrido M, Busse R. Defining the health benefit basket in nine European countries. *The European Journal of Health Economics* 2005;6(1):2–10.
- [86] Krieger LM, Lesavoy MA. Managed care's methods for determining coverage of plastic surgery procedures: the example of reduction mammoplasty. *Plastic and Reconstructive Surgery* 2001;107(5):1234–40.
- [87] Breuning EE, Oikonomou D, Singh P, Raj KI, Mendonca DA. Cosmetic surgery in the NHS: Applying local and national guidelines. *Journal of Plastic, Reconstructive & Aesthetic Surgery* 2010;63(9):1437–42.
- [88] Cook SA, Rosser R, Meah S, James MI, Salmon P. Clinical decision guidelines for NHS cosmetic surgery: analysis of current limitations and recommendations for future development. *British Journal of Plastic Surgery* 2003;56(July (5)):429–36. PubMed PMID: 12890455.
- [89] Henderson J. The plastic surgery postcode lottery in England. *International Journal of Surgery* 2009;7(6):550–8.
- [90] Horner B. Breast augmentation should be on the NHS: A discussion of the ethics of rationing. *Annals of the Royal College of Surgeons of England* 2002;84(2):82–3.
- [91] Kerrigan CL, Collins ED, Kim HM, Schnur PL, Wilkins E, Cunningham B, et al. Reduction mammoplasty: defining medical necessity. *Medical Decision Making* 2002;22(May–June (3)):208–17. PubMed PMID: WOS: 000175746700002. English.
- [92] McClean K, Hanke CW. The medical necessity for treatment of port-wine stains. *Dermatologic Surgery* 1997;23(August (8)):663–7. PubMed PMID: WOS: A1997XP49100009. English.
- [93] Wong AM. The inhumanity of fairness: rationing resources for reconstructive breast surgery. *CMAJ* 1995;152(4):577–9. PubMed PMID: 7859205.
- [94] Benditte-Klepetchko H, Leisser V, Paternostro-Sluga T, Rakos M, Trattinnig S, Helbich T, et al. Hypertrophy of the breast: a problem of beauty or health? *Journal Women's Health* 2007;16(7):1062–9.
- [95] Mukherjee S, Kamat S, Adegbola S, Agrawal S. Funding for postbariatric body-contouring (Bariplastic) surgery in England: a postcode lottery. *Plastic Surgery International* 2014;2014:6.
- [96] Nguyen JT, Wheatley MJ, Schnur PL, Nguyen TA, Winn SR. Reduction mammoplasty: a review of managed care medical policy coverage criteria. *Plastic and Reconstructive Surgery* 2008;121(4):1092–100.
- [97] Stevens RJG, Stevens SG, Rusby JE. The postcode lottery for the surgical correction of gynaecomastia in NHS England. *International Journal of Surgery* 2015;22:22–7.
- [98] Wraight WM, Tay SKL, Nduka C, Pereira JA. Bilateral breast reduction surgery in England: a postcode lottery. *Journal of Plastic, Reconstructive & Aesthetic Surgery* 2007;60(9):1039–44.
- [99] Adler PW. Is it lawful to use Medicaid to pay for circumcision? *Journal of Law, Medicine & Ethics* 2011;19(2):335–53.
- [100] Goodson A, Khoda B, Nduka C. Funding criteria for common procedures: a postcode lottery in NHS plastic surgery. *Journal of Plastic, Reconstructive & Aesthetic Surgery* 2011;64(3):417–9.
- [101] Nicoletti G, Scevola S, Faga A. Is breast reduction a functional or a cosmetic operation? Proposal of an objective discriminating criterion. *Journal of Plastic, Reconstructive & Aesthetic Surgery* 2009;62(12):1644–6.
- [102] Schnur PL, Hoehn JG, Ilstrup DM, Cahoy MJ, Chu C-P. Reduction mammoplasty: cosmetic or reconstructive procedure? *Annals of Plastic Surgery* 1991;27(3):232–7. PubMed PMID: 00000637-199109000-00007.
- [103] True NM. Removing the constraints to coverage of gender-confirming healthcare by state Medicaid programs. *Iowa Law Review* 2012;97(May (4)):1329–62. PubMed PMID: WOS 000303549200009. English.
- [104] Darby R. Targeting patients who cannot object? Re-examining the case for non-therapeutic infant circumcision. *SAGE Open* 2016;6(2).
- [105] Jacobs SA. The determination of medical necessity: Medicaid funding for sex-reassignment surgery. *Case Western Reserve Law Review* 1980;31(1):179–209. PubMed PMID: 11652413.
- [106] Greer AG, Chapman C, Ryckley JB. Moral hazard or morality for health: an ethical debate on insurance coverage for the obese. *Bariatric Surgical Practice and Patient Care* 2012;7(1):36–41.
- [107] Martin LF, White S, Lindstrom Jr W. Cost-benefit analysis for the treatment of severe obesity. *World Journal of Surgery* 1998;22(September (9)):1008–17. PubMed PMID: 9717430.
- [108] Persson U, Willis M, Ödegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. *European Journal of Health Economics* 2010;11(2):195–203.
- [109] Simpson LA, Cooper J. Paying for obesity: a changing landscape. *Pediatrics* 2009;123(Suppl. 5):S301–7.
- [110] Specogna MB. Cessation coverage in Argentina: a qualitative study about its barriers and facilitating factors. *CVD Prevention and Control* 2010;5(1):7–11.
- [111] Kroneman M, de Jong JD. The basic benefit package: composition and exceptions to the rules. A case study. *Health Policy* 2015;119(3):245–51.
- [112] Au-Yeung CM, Weisman SR, Hennrikus DJ, Forster JL, Skoog R, Luneburg W, et al. An evaluation of health benefit modification in taft-hartley health and welfare funds: implications for encouraging tobacco-cessation coverage. *American Journal of Preventive Medicine* 2010;39(6 Suppl. 1):S30–6.
- [113] Heath J, Braun MA, Brindle M. Smokers' rights to coronary artery bypass graft surgery. *JONA'S Healthcare Law, Ethics and Regulation* 2002;4(June (2)):32–5. PubMed PMID: 12042677.
- [114] Woolf NH, Burns ME, Bosworth TW, Fiore MC. Purchasing health insurance coverage for smoking cessation treatment: employers describe the most influential information in this decision. *Nicotine & Tobacco Research* 2006;8(6):717–25.
- [115] Khalid MI. Access to surgery for smokers. Denying treatment is indefensible. *BMJ: British Medical Journal* 1993;306(6889):1408. PubMed PMID: PMC1677845.
- [116] Booth CM, Dranitsaris G, Gainford MC, Berry S, Fralick M, Fralick J, et al. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. *BMC Cancer* 2007;7(1):110.
- [117] Kieslich K, Ahn J, Badano G, Chalkidou K, Cubillos L, Hauengen RC, et al. Public participation in decision-making on the coverage of new antivirals for hepatitis C. *Journal of Health Organization and Management* 2016;30(5):769–85. PMID: 27468625.
- [118] Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. *Pharmacoeconomics* 2014;32(May (5)):509–20. PubMed PMID: WOS 000335757600008. English.
- [119] Cromwell I, Peacock SJ, Mitton C. 'Real-world' health care priority setting using explicit decision criteria: a systematic review of the literature. *BMC Health Services Research* 2015;15(1):1.
- [120] Cerri KH, Knapp M, Fernandez JL. Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making. *European Journal of Health Economics* 2014;15(7):681–95.
- [121] Shah KK, Tsuchiya A, Wailoo AJ. Valuing health at the end of life: an empirical study of public preferences. *European Journal of Health Economics* 2014;15(May (4)):389–99. PubMed PMID: WOS 000334998700006. English.
- [122] Fischer KE. A systematic review of coverage decision-making on health technologies-Evidence from the real world. *Health Policy* 2012;107(2–3):218–30.
- [123] Hasman A, McIntosh E, Hope T. What reasons do those with practical experience use in deciding on priorities for healthcare resources? A qualitative study. *Journal of Medical Ethics* 2008;34(9):658–63.
- [124] Wong G, Greenhalgh T, Pawson R. Internet-based medical education: a realist review of what works, for whom and in what circumstances. *BMC Medical Education* 2010;10(1):1.
- [125] Björk J, Lynoe N, Juth N. Are smokers less deserving of expensive treatment? A randomised controlled trial that goes beyond official values. *BMC Medical Ethics* 2015;16(1):1.
- [126] Tinghög G, Carlsson P, Lyttkens CH. Individual responsibility for what? A conceptual framework for exploring the suitability of private financing in a publicly funded health-care system. *Health Economics Policy Law* 2010;5(2):201–23.
- [127] Rooshenas L, Owen-Smith A, Hollingworth W, Badrinath P, Beynon C, Donovan JL. I won't call it rationing: an ethnographic study of healthcare disinvestment in theory and practice. *Social Science & Medicine* 2015;128:273–81.
- [128] McIver S, Ham C. Five cases, four actors and a moral: lessons from studies of contested treatment decisions. *Health Expectations* 2000;3(2):114–24.
- [129] Gordon EJ. The political contexts of evidence-based medicine: policymaking for daily hemodialysis. *Social Science & Medicine* 2006;62(11):2707–19.